Company intelligence / Profile preview

Walvax Biotechnology Co., Ltd.

Kunming, Yunnan Province, Chinaen.walvax.com ↗

Ownership: Private
Employees: ~2388
Development stage: Commercial

Overview

Walvax has successfully developed and licensed 8 vaccines, including a 13-valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) and HPV vaccines. Their COVID-19 mRNA vaccine (AWcorna/ARCoV) received emergency use approval in Indonesia in September 2022 and in China in December 2023[6][7].

Therapeutic areas: OncologyInfectious Diseases
Modalities: Vaccines (including mRNA vaccines, conjugated vaccines, multivalent vaccines, genetically engineered subunit vaccines)
Industry: Biotech

Drug pipeline

25 assets

Tetanus Vaccine (Adsorbed)

Approved

24 more assets in the full pipeline.

Request access →

Partnerships

Bill & Melinda Gates Foundation (BMGF)Suzhou Abogen BiosciencesPLA Academy of Military Science

Beyond the preview

Go deeper on Walvax Biotechnology Co., Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Walvax Biotechnology Co., Ltd..

Explore the full profile